Scinai Immunotherapeutics Files Updated Business Presentation
Ticker: SCNI · Form: 6-K · Filed: Jun 14, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, presentation, company-update
Related Tickers: SCIN
TL;DR
SCIN just dropped a new investor deck - check for updates.
AI Summary
Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on June 14, 2024, to furnish an updated business presentation. The presentation, filed as Exhibit 99.1, contains new updates regarding the company's business.
Why It Matters
This filing provides investors with the latest information and potential strategic updates from Scinai Immunotherapeutics, which could influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing to provide updated information to investors and does not indicate any immediate financial distress or significant operational change.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer of the report
- BiondVax Pharmaceuticals Ltd. (company) — Former name of the filer
- June 14, 2024 (date) — Filing date
- Exhibit 99.1 (document) — Updated business presentation
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to furnish an updated presentation about Scinai Immunotherapeutics Ltd.'s business, incorporated as Exhibit 99.1.
When was this Form 6-K filed?
This Form 6-K was filed on June 14, 2024.
What was Scinai Immunotherapeutics Ltd. formerly known as?
Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.
What is included as Exhibit 99.1 in this filing?
Exhibit 99.1 is an updated presentation about the Company's business.
Does the company file annual reports under Form 20-F or 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Stats: 263 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-06-14 07:26:27
Filing Documents
- ea0207828-6k_scinai.htm (6-K) — 10KB
- ea020782801ex99-1_scinai.htm (EX-99.1) — 60KB
- ex99-1_001.jpg (GRAPHIC) — 204KB
- ex99-1_002.jpg (GRAPHIC) — 402KB
- ex99-1_003.jpg (GRAPHIC) — 188KB
- ex99-1_004.jpg (GRAPHIC) — 221KB
- ex99-1_005.jpg (GRAPHIC) — 210KB
- ex99-1_006.jpg (GRAPHIC) — 239KB
- ex99-1_007.jpg (GRAPHIC) — 184KB
- ex99-1_008.jpg (GRAPHIC) — 197KB
- ex99-1_009.jpg (GRAPHIC) — 281KB
- ex99-1_010.jpg (GRAPHIC) — 195KB
- ex99-1_011.jpg (GRAPHIC) — 206KB
- ex99-1_012.jpg (GRAPHIC) — 206KB
- ex99-1_013.jpg (GRAPHIC) — 256KB
- ex99-1_014.jpg (GRAPHIC) — 205KB
- ex99-1_015.jpg (GRAPHIC) — 257KB
- ex99-1_016.jpg (GRAPHIC) — 178KB
- ex99-1_017.jpg (GRAPHIC) — 461KB
- ex99-1_018.jpg (GRAPHIC) — 418KB
- ex99-1_019.jpg (GRAPHIC) — 311KB
- ex99-1_020.jpg (GRAPHIC) — 333KB
- ex99-1_021.jpg (GRAPHIC) — 296KB
- ex99-1_022.jpg (GRAPHIC) — 214KB
- ex99-1_023.jpg (GRAPHIC) — 386KB
- ex99-1_024.jpg (GRAPHIC) — 225KB
- ex99-1_025.jpg (GRAPHIC) — 237KB
- ex99-1_026.jpg (GRAPHIC) — 273KB
- ex99-1_027.jpg (GRAPHIC) — 272KB
- ex99-1_028.jpg (GRAPHIC) — 260KB
- ex99-1_029.jpg (GRAPHIC) — 339KB
- ex99-1_030.jpg (GRAPHIC) — 196KB
- ex99-1_031.jpg (GRAPHIC) — 193KB
- ex99-1_032.jpg (GRAPHIC) — 137KB
- ex99-1_033.jpg (GRAPHIC) — 220KB
- ex99-1_034.jpg (GRAPHIC) — 249KB
- ex99-1_035.jpg (GRAPHIC) — 222KB
- ex99-1_036.jpg (GRAPHIC) — 183KB
- ex99-1_037.jpg (GRAPHIC) — 256KB
- ex99-1_038.jpg (GRAPHIC) — 309KB
- ex99-1_039.jpg (GRAPHIC) — 183KB
- ex99-1_040.jpg (GRAPHIC) — 331KB
- ex99-1_041.jpg (GRAPHIC) — 173KB
- ex99-1_042.jpg (GRAPHIC) — 239KB
- ex99-1_043.jpg (GRAPHIC) — 188KB
- ex99-1_044.jpg (GRAPHIC) — 194KB
- 0001213900-24-052622.txt ( ) — 15122KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: June 14, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2